Press release
Osteoarthritis Pipeline Analysis, 2025 by DelveInsight | ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmu
DelveInsight's, "Osteoarthritis - Pipeline Insight, 2025" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Osteoarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Osteoarthritis Pipeline Companies are CytoVac, XNK Therapeutics, NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Innate Pharma, Affimed Therapeutics AG, Wugen, Abivax, Glycostem Therapeutics (IPD Therapeutic), Synimmune, GT Biopharma, Bellicum Pharmaceuticals, Asclepius Technology Company Group, PersonGen BioTherapeutics (Suzhou), Chongqing Sidemu Biotechnology, Artiva Biotherapeutics, NKMax, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Kuur Therapeutics (Formerly Cell Medica), and others.
According to DelveInsight, over 100 companies are actively developing more than 110 therapies for Osteoarthritis.
Osteoarthritis Overview:
Osteoarthritis (OA) is the most common form of arthritis, often called "wear and tear" or degenerative joint disease, and primarily affects the knees, hips, and hands. In OA, the cartilage that cushions the ends of bones gradually wears away, and the underlying bone may undergo structural changes. These changes progress slowly and worsen over time. OA causes symptoms such as joint pain, stiffness, and swelling, and in severe cases, it can significantly limit mobility and disrupt daily activities. Typical signs include pain that worsens with activity and eases with rest, brief stiffness after periods of inactivity (usually under 30 minutes), a sense of joint instability, and sometimes a grinding or creaking sensation during movement. Swelling may also occur, particularly following prolonged joint use.
Download our report @ https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Osteoarthritis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Osteoarthritis Therapeutics Market.
Key Takeaways from the Osteoarthritis Pipeline Report
DelveInsight's Osteoarthritis pipeline report highlights a vibrant landscape with over 100 companies developing more than 110 therapies for osteoarthritis.
Recent regulatory advancements include:
*
March 2025: Doron Therapeutics received RMAT designation for MOTYS, a biologic for knee osteoarthritis, accelerating its development and potential patient access.
*
December 2024: Genascence Corporation's GNSC-001, a gene therapy for knee osteoarthritis, received Fast Track designation, reflecting its potential to provide long-term musculoskeletal relief.
*
October 2024: The FDA granted Fast Track designation to Sun Pharma's MM-II, recognizing its promise in addressing unmet needs in osteoarthritis treatment.
Key companies advancing the osteoarthritis treatment landscape include ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid, Kiadis Pharma, Multimmune GmbH, CytoVac, XNK Therapeutics, NantKwest, Green Cross, HiberCell, Bristol-Myers Squibb, Affimed, Wugen, Abivax, Glycostem, Synimmune, GT Biopharma, Bellicum, Asclepius, PersonGen, Chongqing Sidemu, Artiva, NKMax, Acepodia, Allife, Bright Path, Kuur Therapeutics, and others.
Promising pipeline candidates in various development stages include Monalizumab, NKTR-214 (Bempegaldesleukin), ALT 803, ALECSAT, PNK-007, among others.
Osteoarthritis Pipeline Analysis
The Osteoarthritis pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Osteoarthritis Market.
*
Categorizes Osteoarthritis therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Osteoarthritis drugs under development based on:
*
Stage of development
*
Osteoarthritis Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Osteoarthritis Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Osteoarthritis Licensing agreements
*
Funding and investment activities supporting future Osteoarthritis market advancement.
Request for a sample report @ https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Osteoarthritis Emerging Drugs
*
Lorecivivint: Biosplice Therapeutics
*
EP-104IAR: Eupraxia Pharmaceuticals
*
DFV890: Novartis
*
4P004: 4P-Pharma
*
GNSC 001: Genascence
Osteoarthritis Companies
Over 100 leading companies are actively developing therapies for Osteoarthritis, with Biosplice Therapeutics advancing a candidate into the Phase III stage.
DelveInsight's report covers around 110+ products under different phases of Osteoarthritis clinical trials like
*
Osteoarthritis Late stage Therapies (Phase III)
*
Osteoarthritis Mid-stage Therapies (Phase II)
*
Osteoarthritis Early-stage Therapies (Phase I)
*
Osteoarthritis Pre-clinical and Osteoarthritis Discovery stage Therapies
*
Osteoarthritis Discontinued & Inactive Therapies
Osteoarthritis pipeline report provides the Osteoarthritis therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Osteoarthritis Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Osteoarthritis Therapies and Key Osteoarthritis Companies: Osteoarthritis Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Osteoarthritis Pipeline Therapeutic Assessment
- Osteoarthritis Assessment by Product Type
- Osteoarthritis By Stage
- Osteoarthritis Assessment by Route of Administration
- Osteoarthritis Assessment by Molecule Type
Download Osteoarthritis Sample report to know in detail about the Osteoarthritis treatment market @ Osteoarthritis Therapeutic Assessment [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Osteoarthritis Current Treatment Patterns
4. Osteoarthritis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Osteoarthritis Late-Stage Products (Phase-III)
7. Osteoarthritis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Osteoarthritis Discontinued Products
13. Osteoarthritis Product Profiles
14. Osteoarthritis Key Companies
15. Osteoarthritis Key Products
16. Dormant and Discontinued Products
17. Osteoarthritis Unmet Needs
18. Osteoarthritis Future Perspectives
19. Osteoarthritis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Osteoarthritis Pipeline Reports Offerings [https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=osteoarthritis-pipeline-analysis-2025-by-delveinsight-immunitybio-five-prime-therapeutics-innate-pharma-nektar-therapeutics-cantargia-curetech-dynavax-cellid-company-kiadis-pharma-multimmu]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Osteoarthritis Pipeline Analysis, 2025 by DelveInsight | ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmu here
News-ID: 4168810 • Views: …
More Releases from ABNewswire

ALK NSCLC Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approval …
DelveInsight's, "ALK+ NSCLC Pipeline Insight 2025" report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in ALK+ NSCLC pipeline landscape. It covers the ALK+ NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ALK+ NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment…

Amyotrophic Lateral Sclerosis Pipeline Outlook 2025: Clinical Trial Studies, EMA …
DelveInsight's, "Amyotrophic Lateral Sclerosis Pipeline Insight 2025" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis pipeline landscape. It covers the Amyotrophic Lateral Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Amyotrophic…

NK Cell Therapy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Ap …
DelveInsight's, "NK Cell Therapies Pipeline Insight, 2025" report provides comprehensive insights about 140+ companies and 160+ pipeline drugs in NK Cell Therapies pipeline landscape. It covers the NK Cell Therapies pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NK Cell Therapies pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the…

RNA Interference Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA A …
DelveInsight's, "RNA Interference Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 90+ pipeline drugs in the RNA Interference pipeline landscape. It covers the RNA Interference pipeline drug profiles, including clinical and nonclinical stage products. It also covers the RNA Interference therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment…
More Releases for Osteoarthritis
Osteoarthritis Market Massive Growth opportunity Ahead
Introduction
Osteoarthritis (OA), the most common form of arthritis, remains a significant global health burden, causing pain, mobility limitations, and reduced quality of life for millions. Driven by an aging population, lifestyle-related factors like obesity, and a growing focus on musculoskeletal health, the osteoarthritis market is witnessing notable transformation.
According to Exactitude Consultancy, the global osteoarthritis market was valued at USD 14 billion in 2024 and is projected to reach USD 22…
Rising Sports Injuries Fuel Growth In Osteoarthritis Therapeutics Market: The Dr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Osteoarthritis Therapeutics Market Size Growth Forecast: What to Expect by 2025?
In recent times, the osteoarthritis therapeutics market has seen substantial growth. The market size was $8.17 billion in 2024 and is projected to rise to $8.87 billion in 2025, reflecting an annual compound growth rate (CAGR) of 8.6%.…
Osteoarthritis Treatment Market Trends and Forecast 2034
On March 20, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Osteoarthritis Treatment Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across…
Osteoarthritis Treatment Market
Introduction
Osteoarthritis (OA) is the most common form of arthritis, affecting millions worldwide. It is a degenerative joint disease that primarily impacts the cartilage and causes pain, stiffness, and reduced mobility. The growing prevalence of osteoarthritis, especially among the aging population, has created a significant demand for treatment options. The osteoarthritis treatment market includes various therapeutic approaches, such as medications, physical therapies, and surgical procedures, designed to manage the symptoms and…
Osteoarthritis Therapeutics Market - Finding Freedom from Osteoarthritis: Discov …
Newark, New Castle, USA: The "Osteoarthritis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Osteoarthritis Therapeutics Market: https://www.growthplusreports.com/report/osteoarthritis-therapeutics-market/7779
This latest report researches the industry structure, sales, revenue,…
Osteoarthritis Therapeutics Market: Rising Obese and Geriatric Populations to In …
Industry is experiencing significant growth due to the rapid growth in the geriatric and obese population and the associated increase in the prevalence of osteoarthritis disease. Risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment is likely to hamper the growth of the market.
What the Osteoarthritis Therapeutics Market Looks Like?
The osteoarthritis therapeutics market is projected to reach USD 10.1 billion by 2024 from USD 6.8…